Another Genmab drug from Janssen receives breakthrough therapy designation
![Photo: Joost Melis / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13024900.ece/ALTERNATES/schema-16_9/doc7g1rvxhuk7qwq5ps7ff.jpg)
Shortly after Janssen secured approval from the US Food and Drug Administration (FDA) for the Genmab-developed lung cancer drug Rybrevant, the pharmaceutical company has taken a crucial step with another drug from Genmab's Duobody platform.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.